Mount Sinai Health System, based in New York City, will adopt an artificial intelligence-powered platform from SOPHiA GENETICS to expand its cancer research and genomic testing capabilities.
The health system plans to use the SOPHiA DDM Platform to strengthen next-generation sequencing for both blood cancers and solid tumors, supporting care for more than 4,000 oncology patients annually. Mount Sinai is a National Cancer Institute-designated comprehensive cancer center.
The platform is designed to detect and interpret complex genomic variants while streamlining laboratory workflows, reducing manual analysis time and consolidating multiple steps in the testing process, according to an April 16 news release.
Mount Sinai’s molecular pathology team will use the technology to analyze genomic data at scale and improve operational efficiency.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
